Effects of combined use of ribociclib with PARP1 inhibitor on cell kinetics in breast cancer

Creative Commons License

Pulat E., Topçul M. R.

ONCOLOGY LETTERS, cilt.27, sa.6, ss.1-8, 2024 (SCI-Expanded)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 6
  • Basım Tarihi: 2024
  • Doi Numarası: 10.3892/ol.2024.14376
  • Dergi Adı: ONCOLOGY LETTERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS
  • Sayfa Sayıları: ss.1-8
  • İstanbul Üniversitesi Adresli: Evet

Özet

In the present study, antiproliferative and anticancer effects of Valamor (VLM), which contains the active compo‑ nent ribociclib, and DPQ, a poly(ADP‑ribose) polymerase 1 inhibitor, alone and in combination were evaluated in the MCF‑7 and MDA‑MB‑231 breast cancer cell lines in vitro. VLM was applied at concentrations of 40, 80 and 160 µg/ml, and DPQ was used at concentrations of 3, 6 and 9 µg/ml. The proliferation rate, cell index obtained from the real‑time cell analysis system, mitosis activity, bromodeoxyuridine cell proliferation and caspase activity parameters were deter‑ mined. In conclusion, the results obtained from cell kinetics parameters demonstrated the anticancer and antiproliferative effects of the combination of VLM and DPQ on breast cancer cells.